Trials / Conditions / Advanced Breast Carcinoma

Advanced Breast Carcinoma

17 registered clinical trials studyying Advanced Breast Carcinoma — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Living Well With Advanced Breast Cancer NCT07227038	Ohio State University Comprehensive Cancer Center	—
Recruiting	Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow A NCT06486883	MedSIR	Phase 2
Active Not Recruiting	A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Brea NCT06630325	OHSU Knight Cancer Institute	Phase 2
Recruiting	At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860	Mayo Clinic	Phase 2
Unknown	Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer NCT06243432	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Withdrawn	SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831	OHSU Knight Cancer Institute	EARLY_Phase 1
Recruiting	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942	National Cancer Institute (NCI)	Phase 1
Recruiting	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661	National Cancer Institute (NCI)	Phase 1
Terminated	Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225	Nuvation Bio Inc.	Phase 1
Recruiting	Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Ca NCT04090567	M.D. Anderson Cancer Center	Phase 2
Completed	Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Can NCT03207529	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positi NCT03281902	Mayo Clinic	—
Active Not Recruiting	TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast NCT03179904	Mayo Clinic	Phase 2
Terminated	Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer NCT02474173	National Cancer Institute (NCI)	Phase 1
Completed	Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer NCT02270372	Cascadian Therapeutics Inc.	Phase 1